Aimei Health Technology Reports Q1 2026 Financial Results, Net Income Declines to $45,440

Aimei Health Technology Co., Ltd. reported its financial results for the first quarter of 2026, revealing a net income of $45,440, a decrease from the $184,662 reported in the same period of 2025. The company attributed this decline primarily to a significant drop in interest income earned on cash held in trust, which fell to $107,424 from $598,076 year-over-year. General, administrative, and operational costs also decreased to $61,984 from $413,414, reflecting a reduction in operational expenses as the company continues to focus on its strategic objectives.

As of March 31, 2026, Aimei Health's total assets amounted to $12.29 million, up from $12.10 million at the end of 2025. The increase was largely driven by cash held in the Trust Account, which rose to $12.28 million from $12.10 million. However, the company reported a working capital deficit of approximately $3.50 million, indicating ongoing financial challenges as it seeks to complete its initial business combination. The total liabilities also increased slightly to $4.21 million from $4.06 million, primarily due to an increase in extension loans from related parties.

In terms of strategic developments, Aimei Health is in the process of finalizing a business combination with United Hydrogen Group Inc., which was announced in June 2024. The merger agreement is subject to various conditions, including regulatory approvals, and the company anticipates closing the transaction in late 2026. The company has been actively extending the time available to consummate this business combination, with recent extension loans from its sponsor and related parties to facilitate this process.

Operationally, Aimei Health has not yet commenced any revenue-generating activities, as it remains focused on identifying and evaluating potential target businesses for acquisition. The company has maintained a consistent employee headcount of 2,126,000 ordinary shares issued and outstanding, excluding shares subject to possible redemption. The company’s liquidity position is supported by cash reserves, with $18,516 in its operating bank account as of the end of the quarter.

Looking ahead, Aimei Health's management has expressed uncertainty regarding its ability to complete a business combination within the prescribed timeframe, raising concerns about its ability to continue as a going concern. The company has indicated that if it fails to complete the merger by the deadline, it may be required to cease operations and liquidate. As such, the management is actively pursuing opportunities to finalize the merger and is focused on maintaining its financial stability during this critical period.